NCT06104644Active, not recruiting
A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany
Deucravacitinib in Routine Clinical Practice: A 5-year, Multicenter, Prospective, Non-Interventional Cohort Study to Evaluate Effectiveness and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN)
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year period
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 550 (estimated)
- First submitted
- 6 Oct 2023
- Start date
- 13 Apr 2023
- Primary completion date
- 18 Aug 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Psoriasis
- NCT number
- NCT06104644
What you commit to
- Study type: Observational
- Planned participants: 550
- From 13 Apr 2023 to the primary completion date, 18 Aug 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with deucravacitinib
Other
- Any contraindications according to the approved deucravacitinib Summary of Product Characteristics
- Simultaneous participation in an interventional clinical trial for moderate-to-severe psoriasis
Who the study is looking for
- Patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasis initiating deucravacitinib according to approved label in the European Union
- The decision upon treatment with deucravacitinib must have been made before enrollment and independently of this non-interventional observational study
- Patient is at least 18 years of age at the time of treatment decision
- Patient provided written informed consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dermatologische Spezial- und Schwerpunktpraxis Selters Coordinator of this site? Confirm its status | Selters | Germany | Unknown status |
| Local Institution - 0001 Coordinator of this site? Confirm its status | Selters | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.